Upcoming Shuttle Sessions

In vivo Shuttle session


Explicyte is indeed planning a new in vivo shuttle session by mid-October, to be held on a series of syngeneic tumor-bearing mouse models such as MCA025 sarcoma, 4T1 & EMT6 breast cancer, MC38 & CT26 colon cancer or Renca renal cancer, among others. These models can be run either for only efficacy monitoring or for a comprehensive assessment based on a multiparametric platform strategy for a deeper understanding of how a cancer therapy performs.